癌症患者中与免疫检查点抑制剂相关的风湿性疾病:临床特征及其与肿瘤缓解的关系:一项单中心前瞻性队列研究
该单中心前瞻性观察研究纳入2015年9月至2017年5月接受免疫检查点抑制剂(ICI)治疗的524例癌症患者,35例(6.6%)因风湿性免疫相关不良事件(irAEs)转诊风湿科。风湿性irAEs主要表现为炎症性关节炎(3.8%)和非炎症性肌肉骨骼疾病(2.8%),绝大多数发生于抗PD-1/PD-L1抗体治疗,中位暴露时间70天。发生风湿性irAEs的患者肿瘤缓解率显著高于无irAEs患者(85.7% vs 35.3%;P<0.0001)。
要点
- 524例接受ICI治疗的癌症患者中35例(6.6%)因风湿性irAEs转诊风湿科。
- 风湿性irAEs几乎均发生于抗PD-1/PD-L1抗体,中位暴露时间70天。
- 发生风湿性irAEs者肿瘤缓解率85.7% vs 无irAEs者35.3%(P<0.0001)。
核心结论
- ICI使用日益频繁,了解风湿性irAEs及其管理具有重要意义。
- 所有患者对低至中等剂量泼尼松或对症治疗有反应,且无需停用ICI。
- 发生风湿性irAEs的患者肿瘤缓解率显著更高。
研究设计与样本
- 单中心前瞻性观察性研究,纳入所有接受ICI治疗的癌症患者。
- 定期评估irAEs发生情况和肿瘤缓解。
- 出现肌肉骨骼症状的患者转诊至风湿科进行临床评估和管理。
主要发现
- 2015年9月至2017年5月,524例患者接受ICI治疗,35例(6.6%)转诊风湿科。
- 除1例外,所有风湿性irAEs均发生于抗PD-1/PD-L1抗体,中位暴露时间70天。
- 炎症性关节炎占3.8%,模拟类风湿关节炎(n=7)、风湿性多肌痛(n=11)或银屑病关节炎(n=2)。
- 非炎症性肌肉骨骼疾病占2.8%(n=15)。
- 1例类风湿关节炎患者抗环瓜氨酸肽(anti-CCP)阳性。
临床怎么用
- 出现肌肉骨骼症状的患者应转诊至风湿科进行临床评估和管理。
- 炎症性关节炎患者可使用低至中等剂量泼尼松,19例需要糖皮质激素,2例开始甲氨蝶呤。
- 非炎症性肌肉骨骼疾病使用非甾体抗炎药、镇痛药和/或物理治疗。
- 除1例外,患者继续ICI治疗,未因风湿性irAEs停用ICI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response. METHODS: This was a single-centre prospective observational study including all cancer patients receiving ICIs. The occurrence of irAEs and tumour response was assessed on a regular basis. Patients who experienced musculoskeletal symptoms were referred to the department of rheumatology for clinical evaluation and management. RESULTS: From September 2015 to May 2017, 524 patients received ICIs and 35 were referred to the department of rheumatology (6.6%). All but one of the rheumatic irAEs occurred with anti-programmed cell death protein 1(PD-1)/PD-1 ligand 1(PD-L1) antibodies, with a median exposure time of 70 days. There were two distinct clinical presentations: (1) inflammatory arthritis (3.8%) mimicking either rheumatoid arthritis (n=7), polymyalgia rheumatica (n=11) or psoriatic arthritis (n=2) and (2) non-inflammatory musculoskeletal conditions (2.8%; n=15). One patient with rheumatoid arthritis was anti-cyclic citrullinated peptide (anti-CCP) positive. Nineteen patients required glucocorticoids, and methotrexate was started in two patients. Non-inflammatory disorders were managed with non-steroidal anti-inflammatory drugs, analgesics and/or physiotherapy. ICI treatment was pursued in all but one patient. Patients with rheumatic irAEs had a higher tumour response rate compared with patients without irAEs (85.7% vs 35.3%; P<0.0001). CONCLUSION: Since ICIs are used with increasing frequency, knowledge of rheumatic irAEs and their management is of major interest. All patients were responsive either to low-to-moderate doses of prednisone or symptomatic therapies and did not require ICI discontinuation. Furthermore, tumour response was significantly higher in patients who experienced rheumatic irAEs.
引用
- Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2017. PMID: 29146737. doi:10.1136/annrheumdis-2017-212257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。